Medivir AB announced improved durable clinical benefit in maturing data from the ongoing phase 1b/2a study in advanced hepatocellular carcinoma (HCC), measured by local review. These data, where all patients have had minimum 12 weeks follow-up, further supports accelerating the fostrox development program to initiate a registrational phase 2b study in second-line HCC in 2024. The data is from a phase 1b/2a open-label, multi-center, dose-escalation and dose-expansion study evaluating the safety and efficacy with fostroxacitabine bralpamide (fostrox) in combination with Lenvima®?

in patients for whom current first- or second-line treatment has proven ineffective or is not tolerable. The study is ongoing with ~50% of patients still on treatment and all patients have had minimum12 weeks follow-up. The combination remains tolerable with no unexpected new safety events and lower need for dose reductions than expected.

Additional data from the ongoing phase 1ss/2a study will be presented at the ASCO Gastrointestinal Cancers Symposium, January 18-20, 2024 in San Francisco, USA. The abstract, titled "First safety and efficacy data from phase Ib/IIa study of fostroxacitabine Bralpamide (fost approx, MIV-818) in combination with lenvatinib in patients with hepatocellular carcinoma ("HCC)" will be presented by Dr. Maria Reig, Director of the Barcelona Clinic Liver Cancer (BCLC) and the Liver Oncology Unit at the Hospital Clinic of Barcelona in Spain on January 19th.